Bevacizumab Distribution Into Ascitic Fluid Decreases Serum Drug Exposure: A Case of Metastatic Colon Cancer

Ther Drug Monit. 2021 Dec 1;43(6):813-814. doi: 10.1097/FTD.0000000000000926.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Angiogenesis Inhibitors
  • Ascitic Fluid* / pathology
  • Bevacizumab / therapeutic use
  • Colonic Neoplasms* / drug therapy
  • Colonic Neoplasms* / pathology
  • Humans

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab